Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patients

M. Solar, E. Malirova, M. Ballon, R. Pelouch, J. Ceral,

. 2012 ; 166 (4) : 679-86. [pub] 20120117

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12024109

OBJECTIVE: Confirmatory testing of suspected primary aldosteronism (PA) requires an extensive medication switch that can be difficult for patients with severe complicated hypertension and/or refractory hypokalemia. For this reason, we investigated the effect of chronic antihypertensive medication on confirmatory testing results. To allow the results to be interpreted, the reproducibility of confirmatory testing was also evaluated. DESIGN AND METHODS: The study enrolled 114 individuals with suspected PA who underwent two confirmatory tests. The patients were divided into two groups. In Group A, both tests were performed on the guidelines-recommended therapy, i.e. not interfering with the renin-angiotensin-aldosterone system. In Group B, the first test was performed on chronic therapy with the exclusion of thiazides, loop diuretics, and aldosterone antagonists; and the second test was performed on guidelines-recommended therapy. Saline infusion, preceded by oral sodium loading, was used to suppress aldosterone secretion. RESULTS: Agreement in the interpretation of the two confirmatory tests was observed in 84 and 66% of patients in Groups A and B respectively. For all 20 individuals in Group A who ever had end-test serum aldosterone levels ≥240 pmol/l, aldosterone was concordantly nonsuppressible during the other test. Similarly, for all 16 individuals in Group B who had end-test serum aldosterone levels ≥240 pmol/l on modified chronic therapy, aldosterone remained nonsuppressible with guidelines-recommended therapy. CONCLUSION: Confirmatory testing performed while the patient is on chronic therapy without diuretics and aldosterone antagonists can confirm the diagnosis of PA, provided serum aldosterone remains markedly elevated at the end of saline infusion.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12024109
003      
CZ-PrNML
005      
20121207100901.0
007      
ta
008      
120815e20120117enk f 000 0#eng||
009      
AR
024    7_
$a 10.1530/eje-11-0914 $2 doi
035    __
$a (PubMed)22253400
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Solar, Miroslav $u Departments of Internal Medicine Nuclear Medicine, Charles University Prague, University Hospital Hradec Kralove, Sokolska 581, Hradec Kralove, Czech Republic.
245    10
$a Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patients / $c M. Solar, E. Malirova, M. Ballon, R. Pelouch, J. Ceral,
520    9_
$a OBJECTIVE: Confirmatory testing of suspected primary aldosteronism (PA) requires an extensive medication switch that can be difficult for patients with severe complicated hypertension and/or refractory hypokalemia. For this reason, we investigated the effect of chronic antihypertensive medication on confirmatory testing results. To allow the results to be interpreted, the reproducibility of confirmatory testing was also evaluated. DESIGN AND METHODS: The study enrolled 114 individuals with suspected PA who underwent two confirmatory tests. The patients were divided into two groups. In Group A, both tests were performed on the guidelines-recommended therapy, i.e. not interfering with the renin-angiotensin-aldosterone system. In Group B, the first test was performed on chronic therapy with the exclusion of thiazides, loop diuretics, and aldosterone antagonists; and the second test was performed on guidelines-recommended therapy. Saline infusion, preceded by oral sodium loading, was used to suppress aldosterone secretion. RESULTS: Agreement in the interpretation of the two confirmatory tests was observed in 84 and 66% of patients in Groups A and B respectively. For all 20 individuals in Group A who ever had end-test serum aldosterone levels ≥240 pmol/l, aldosterone was concordantly nonsuppressible during the other test. Similarly, for all 16 individuals in Group B who had end-test serum aldosterone levels ≥240 pmol/l on modified chronic therapy, aldosterone remained nonsuppressible with guidelines-recommended therapy. CONCLUSION: Confirmatory testing performed while the patient is on chronic therapy without diuretics and aldosterone antagonists can confirm the diagnosis of PA, provided serum aldosterone remains markedly elevated at the end of saline infusion.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a aldosteron $x krev $7 D000450
650    _2
$a antagonisté mineralokortikoidních receptorů $x aplikace a dávkování $x terapeutické užití $7 D000451
650    _2
$a algoritmy $7 D000465
650    _2
$a antihypertenziva $x aplikace a dávkování $x terapeutické užití $7 D000959
650    _2
$a diagnostické techniky endokrinologické $7 D003940
650    _2
$a diuretika $x aplikace a dávkování $x terapeutické užití $7 D004232
650    _2
$a náhrada léků $x využití $7 D057915
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hyperaldosteronismus $x diagnóza $x farmakoterapie $x epidemiologie $7 D006929
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a odhad potřeb $x statistika a číselné údaje $7 D020380
650    _2
$a renin-angiotensin systém $x účinky léků $x fyziologie $7 D012084
650    _2
$a validační studie jako téma $7 D054928
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Malirova, Eva
700    1_
$a Ballon, Marek
700    1_
$a Pelouch, Radek
700    1_
$a Ceral, Jiri
773    0_
$w MED00009634 $t European journal of endocrinology / European Federation of Endocrine Societies $x 1479-683X $g Roč. 166, č. 4 (20120117), s. 679-86
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22253400 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120815 $b ABA008
991    __
$a 20121207100935 $b ABA008
999    __
$a ok $b bmc $g 946257 $s 781437
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 166 $c 4 $d 679-86 $e 20120117 $i 1479-683X $m European journal of endocrinology $n Eur J Endocrinol $x MED00009634
LZP    __
$a Pubmed-20120815/12/02

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...